Allena Pharmaceuticals, Inc. (ALNAQ) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Newton, MA, United States.
ALNAQ has IPO date of 2017-11-02, 12 full-time employees, listed on the Other OTC, a market capitalization of $122.00.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
